Advertisement

Quality of Life and Motor Outcomes in Patients With Parkinson’s Disease 12 Months After Deep Brain Stimulation in China

Published:November 18, 2022DOI:https://doi.org/10.1016/j.neurom.2022.10.047

      Abstract

      Background

      Long-term levodopa use is frequently associated with fluctuations in motor response and can have a serious adverse effect on the quality of life (QoL) of patients with Parkinson’s disease (PD). Deep brain stimulation (DBS) is effective in improving symptoms of diminished levodopa responsiveness. QoL improvements with DBS have been shown in several randomized control trials, mostly in Europe and the United States; however, there is a need for evidence from regions around the world.

      Objective

      The study aimed to demonstrate improvement in PD-related QoL in patients undergoing DBS in a prospective, multicenter study conducted in China.

      Materials and Methods

      To evaluate the effect of neurostimulation on the QoL of patients with PD, a Parkinson’s Disease Questionnaire (PDQ-8); Unified Parkinson’s Disease Rating Scale (UPDRS) I, II, III, and IV; and EuroQol 5-dimension questionnaire (EQ-5D) were administered at baseline and 12 months after DBS implantation. The mean change and percent change from baseline were reported for these clinical outcomes.

      Results

      Assessments were completed for 85 of the 89 implanted patients. DBS substantially improved patients’ QoL and function. Implanted patients showed statistically significant mean improvement in PDQ-8 and UPDRS III (on stimulation/off medication). In the patients who completed the 12-month follow-up visit, the percent change was −22.2% for PDQ-8 and −51.6% for UPDRS III (on stimulation/off medication). Percent change from baseline to 12 months for UPDRS I, II, III, and IV and EQ-5D were −16.8%, −39.4%, −18.5%, and −50.0% and 22.7%, respectively. The overall rate of incidence for adverse events was low at 15.7%. Favorable outcomes were also reported based on patient opinion; 95.3% were satisfied with DBS results.

      Conclusions

      These data were comparable to other studies around the world and showed alignment with the ability of DBS to meaningfully improve the QoL of patients with PD. More studies investigating DBS therapy for patients with PD are necessary to accurately characterize clinical outcomes for the global PD population.

      Clinical Trial Registration

      The ClinicalTrials.gov registration number for this study is NCT02937688.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gandhi K.R.
        • Saadabadi A.
        Levodopa (L-dopa).
        in: StatPearls [Internet]. StatPearls Publishing, 2022
        • Tambasco N.
        • Romoli M.
        • Calabresi P.
        Levodopa in Parkinson’s disease: current status and future developments.
        Curr Neuropharmacol. 2018; 16: 1239-1252
        • Aum D.J.
        • Tierney T.S.
        Deep brain stimulation: foundations and future trends.
        Front Biosci (Landmark Ed). 2018; 23: 162-182
        • Peng L.
        • Fu J.
        • Ming Y.
        • Zeng S.
        • He H.
        • Chen L.
        The long-term efficacy of STN vs GPi deep brain stimulation for Parkinson disease: a meta-analysis.
        Medicine (Baltimore). 2018; 97e12153
        • Hacker M.L.
        • Turchan M.
        • Heusinkveld L.E.
        • et al.
        Deep brain stimulation in early-stage Parkinson disease: five-year outcomes.
        Neurology. 2020; 95: e393-e401
        • Merola A.
        • Romagnolo A.
        • Krishna V.
        • et al.
        Current directions in deep brain stimulation for Parkinson’s disease-directing current to maximize clinical benefit.
        Neurol Ther. 2020; 9: 25-41
        • Volkmann J.
        • Wolters A.
        • Kupsch A.
        • et al.
        Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial.
        Lancet Neurol. 2012; 11: 1029-1038
        • Schuepbach W.M.
        • Rau J.
        • Knudsen K.
        • et al.
        Neurostimulation for Parkinson’s disease with early motor complications.
        N Engl J Med. 2013; 368: 610-622
        • Katz M.
        • Luciano M.S.
        • Carlson K.
        • et al.
        Differential effects of deep brain stimulation target on motor subtypes in Parkinson’s disease.
        Ann Neurol. 2015; 77: 710-719
        • Odekerken V.J.
        • Boel J.A.
        • Schmand B.A.
        • et al.
        GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up.
        Neurology. 2016; 86: 755-761
        • Rodriguez-Oroz M.C.
        • Obeso J.A.
        • Lang A.E.
        • et al.
        Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up.
        Brain. 2005; 128: 2240-2249
        • Fasano A.
        • Romito L.M.
        • Daniele A.
        • et al.
        Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants.
        Brain. 2010; 133: 2664-2676
      1. Bove F, Mulas D, Cavallieri F, et al. Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology. Published online June 2, 2021. https://doi.org/10.1212/WNL.0000000000012246

        • Marras C.
        • Beck J.C.
        • Bower J.H.
        • et al.
        Prevalence of Parkinson’s disease across North America.
        NPJ Parkinsons Dis. 2018; 4: 21
        • Balestrino R.
        • Schapira A.H.V.
        Parkinson disease.
        Eur J Neurol. 2020; 27: 27-42
        • von Campenhausen S.
        • Bornschein B.
        • Wick R.
        • et al.
        Prevalence and incidence of Parkinson’s disease in Europe.
        Eur Neuropsychopharmacol. 2005; 15: 473-490
        • Jiang L.L.
        • Liu J.L.
        • Fu X.L.
        • et al.
        Long-term efficacy of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a 5-year follow-up study in China.
        Chin Med J (Engl). 2015; 128: 2433-2438
        • Chan D.T.
        • Zhu C.X.
        • Lau C.K.
        • et al.
        Subthalamic nucleus deep brain stimulation for Parkinson disease in Hong Kong: a prospective territory-wide 2-year follow-up study.
        World Neurosurg. 2016; 93: 229-236
        • Kishore A.
        • Rao R.
        • Krishnan S.
        • et al.
        Long-term stability of effects of subthalamic stimulation in Parkinson’s disease: Indian experience.
        Mov Disord. 2010; 25: 2438-2444
        • Conway Z.J.
        • Silburn P.A.
        • Perera T.
        • O’Maley K.
        • Cole M.H.
        Low-frequency STN-DBS provides acute gait improvements in Parkinson’s disease: a double-blinded randomised cross-over feasibility trial.
        J Neuroeng Rehabil. 2021; 18: 125
        • Sharma A.
        • Palaniappan L.
        Improving diversity in medical research.
        Nat Rev Dis Primers. 2021; 7: 74
        • Uitti R.
        • Marras C.
        • Dodel R.
        • et al.
        Parkinson’s Disease Data Collection Reference Guide.
        International Consortium for Health Outcome Measurement, 2015
        • Chen K.
        • Yang Y.J.
        • Liu F.T.
        • et al.
        Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study.
        Health Qual Life Outcomes. 2017; 15: 170
        • Luo N.
        • Liu G.
        • Li M.
        • Guan H.
        • Jin X.
        • Rand-Hendriksen K.
        Estimating an EQ-5D-5L value set for China.
        Value Health. 2017; 20: 662-669
        • Chinese Research Group on Deep Brain Stimulation in Parkinson’s Disease
        Chinese expert consensus on deep brain stimulation therapy in Parkinson’s disease.
        Chin J Neurol. 2012; 45: 541-543
        • Hochberg Y.
        A sharper Bonferroni procedure for multiple tests of significance.
        Biometrika. 1988; 75: 800-802
        • Stebbins G.T.
        • Goetz C.G.
        • Burn D.J.
        • Jankovic J.
        • Khoo T.K.
        • Tilley B.C.
        How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale.
        Mov Disord. 2013; 28: 668-670
        • Neumann W.J.
        • Staub F.
        • Horn A.
        • et al.
        Deep brain recordings using an implanted pulse generator in Parkinson’s disease.
        Neuromodulation. 2016; 19: 20-24
        • Dorsey E.R.
        • Constantinescu R.
        • Thompson J.P.
        • et al.
        Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
        Neurology. 2007; 68: 384-386

      Comments